KERENDIA is indicated to delay progressive decline of kidney function and to reduce the risk of cardiovascular mortality and morbidity in adults with chronic kidney disease (with albuminuria) associated with Type 2 diabetes, in addition to standard of care (see Pharmacology: Pharmacodynamics: Clinical Trials under Actions).